Understanding the Market | LEADS BIOLABS-B rises over 6% again as Vailixin's Phase II study for frontline treatment of hepatocellular carcinoma enters the expansion stage
I'm LongbridgeAI, I can summarize articles.LEADS BIOLABS-B rose over 6% again, with a cumulative increase of over 36% this month. As of the time of writing, it rose 6.07% to HKD 73.35, with a trading volume of HKD 131 million. In terms of news, LEADS BIOLABS recently announced that its self-developed PD-L1/4-1BB bispecific antibody, LBL-024, has completed the safety induction phase assessment of the Phase II clinical study for the first-line treatment of hepatocellular carcinoma, successfully entering the expansion phase. Public information shows that LBL-024 has demonstrated strong efficacy signals and breakthrough therapeutic potential in multiple tumor types, including lung neuroendocrine carcinoma, non-small cell lung cancer, small cell lung cancer, and cholangiocarcinoma. Based on the conditional activation design of the X-body® platform, its good safety has been validated in nearly 800 patients. This validation in liver cancer further solidifies LBL-024 as a safe cornerstone therapy for IO 2.0 pan-tumor treatment
According to Zhitong Finance APP, LEADS BIOLABS-B (09887) has risen over 6% again, with a cumulative increase of over 36% this month. As of the time of publication, it is up 6.07%, priced at HKD 73.35, with a transaction volume of HKD 131 million.
In terms of news, LEADS BIOLABS recently announced that its self-developed PD-L1/4-1BB bispecific antibody, LBL-024, has completed the safety induction phase assessment of its Phase II clinical study for the first-line treatment of hepatocellular carcinoma, successfully entering the expansion phase after expert review.
Public information shows that LBL-024 has demonstrated strong efficacy signals and breakthrough therapeutic potential in multiple tumor types, including pulmonary neuroendocrine carcinoma, non-small cell lung cancer, small cell lung cancer, and cholangiocarcinoma. Based on the conditional activation design of the X-body® platform, its good safety has been validated in nearly 800 patients. This further validation in liver cancer solidifies LBL-024 as a safe cornerstone therapy for IO 2.0 pan-tumor treatment